CClinicalTrials.gg
RecruitingNCT06157684Updated Dec 6, 2023

Timing of Ambulation and Infant Birth Weight in Gestational Diabetes

An interventional study of Postprandial ambulation in Gestational Diabetes, Pregnancy Complications and Pregnancy in Diabetic, sponsored by Women and Infants Hospital of Rhode Island. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Women and Infants Hospital of Rhode Island · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

This is a randomized controlled trial to assess the effect of routine exercise counseling compared to the recommendation for postprandial ambulation on infant birthweight among pregnant people with gestational diabetes mellitus.

The primary outcome is birthweight percentile for gestational age at delivery.

Secondary outcomes include feasibility and acceptability, need for metformin or insulin for glycemic control, mode of delivery, neonatal hypoglycemia.

Participants will be counseled to either complete 20 minutes of walking after meals, or be counseled with routine exercise counseling of 30 minutes of low-impact 5x a week. Their activity will be tracked by "FitBit" pedometers and uploaded via bluetooth to a database for review. They will continue to receive routine obstetric and diabetes care.

Read the detailed description

This is a randomized controlled trial of postprandial ambulation to decrease birthweight percentile in patients with gestational diabetes.

Patients who are diagnosed with gestational diabetes. and enrolled in the Diabetes in Pregnancy Program in the Division of Maternal Fetal Medicine at Women and Infants Hospital of Rhode Island will be approach for inclusion in the study. After consent is obtained, patients with gestational diabetes. will be randomized into one of two groups.

  • Group 1: intervention group: 20 minutes of walking after meals
  • Group 2: non-intervention group: routine activity

Randomization will occur via computer generated randomization in blocks of 10. After consent is obtained the participants will be randomized via REDCap. They will then receive counseling specific to their group. They will be provided with an activity monitor and instructed on how to use as well as charge and upload data. They will be provided with the information from the manufacturer as well as trouble shooting guide.

As is the standard of care in this clinic, both groups would be equipped with glucometers and diabetic testing supplies. Both groups would receive the same diabetes and nutrition counseling from qualified nursing staff. Additionally, all participants will be provided with Bluetooth enabled pedometers. Those participants assigned to the intervention group would be instructed to walk for 20 minutes within the first two hours following each meal, while those assigned to the routine activity group will receive standard exercise counseling per American College of Obstetricians and Gynecologists and the American Diabetes Association.

Patients will touch base weekly (either in person or by email) with diabetic nurse educators as is the standard management in this clinic. The decision to start insulin for glucose management will remain up to the discretion of the participant's medical doctor. In addition to review of their glucose logs, patients will review activity log and pedometer data with research staff on a weekly or biweekly basis.

Delivery data will be collected on all patients including routine postpartum laboratory data.

02

Conditions studied

  • Gestational Diabetes
  • Pregnancy Complications
  • Pregnancy in Diabetic
  • Fetal Macrosomia
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who are diagnosed with gestational diabetes and receive care at the Maternal Fetal Medicine Diabetes in Pregnancy Program and who are fluent in English or Spanish.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing type 1 or type 2 diabetes, and those diagnosed with gestational diabetes in the first trimester. Patients who are either physically unable to ambulate or who have other contraindications to ambulation.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Postprandial Ambulation

    Participants are counseled to walk for 20 minutes within 2 hours following meals daily.

    Behavioral: Postprandial ambulation

  • No intervention
    Routine exercise counseling

    Participants are counseled on routine ADA recommendations for 30 minutes of low-impact exercise 5 times a week

Interventions

  • BehavioralPostprandial ambulation

    See arm description

05

What researchers measure

Primary outcomes

  1. Infant birthweight percentile

    Birthweight percentile for gestational age for neonatal sex

    Time frame: Single time point - at birth

Secondary outcomes

  1. infant birthweight

    birthweight measured after delivery

    Time frame: Single time point - at birth

  2. neonatal hypoglycemia treatment

    need for PO or IV treatment for neonatal hypoglycemia

    Time frame: within 48 hours of birth

  3. mode of delivery

    spontaneous vaginal, operative vaginal, cesarean delivery

    Time frame: Single time point

  4. fetal macrosomia

    birthweight \>4500 gm

    Time frame: Single time point - at birth

  5. need for insulin or metformin during pregnancy

    need for initiation of anti-hyperglycemic treatment during pregnancy

    Time frame: from diagnosis to delivery of infant

Other outcomes

  1. feasibility and acceptability

    Likert scale for participant experience

    Time frame: 3 months after the study conclusion

06

Study locations

1 of 1 sites recruiting
  • Women & Infants Hospital of Rhode Island
    Providence, Rhode Island 02905, United States
    Recruiting
07

References and documents

Study documents

  • Study protocol · Sep 19, 2022
  • Informed consent form · Mar 20, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT06157684
Lead sponsor
Women and Infants Hospital of Rhode Island
Responsible party
Anna Whelan (Clinical and Research Fellow, Principal Investigator, Women and Infants Hospital of Rhode Island) — Principal investigator
First posted
Dec 6, 2023
Start date
Oct 1, 2022
Primary completion
Oct 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Dec 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion